Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
The treatment of inflammatory bowel diseases (IBD) can be challenging, especially in elderly multimorbid patients. Since incidence and prevalence rates of IBD are rising steadily, treatment of older patients with relevant and also rare comorbidities will be of increasing relevancy for caregivers. He...
Main Authors: | Holger Schäffler, Astrid Huth, Georg Lamprecht, Olaf Anders |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-12-01
|
Series: | Case Reports in Gastroenterology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/485372 |
Similar Items
-
Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
by: Dart RJ, et al.
Published: (2017-03-01) -
Selective biologics for ulcerative colitis and Crohn's disease – clinical utility of vedolizumab
by: Petkau JM, et al.
Published: (2016-03-01) -
Primary sclerosing cholangitis associated with severe ulcerative colitis in a young man
by: José Cândido Caldeira Xavier Júnior, et al.
Published: (2013-12-01) -
Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study
by: Jeong Yeon Kim, et al.
Published: (2020-03-01) -
Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK
by: Wilson MR, et al.
Published: (2017-10-01)